| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Slit2 |
| Uniprot No | O94813 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 全长 |
| 氨基酸序列 | full |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Slit2重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *Slit proteins bind Robo receptors and have an evolutionarily conserved role in repulsive axon guidance*
**作者**: Brose, K. et al.
**摘要**: 该研究首次报道了哺乳动物Slit2重组蛋白的纯化及其功能。发现Slit2通过结合Roundabout (Robo) 受体介导轴突导向的排斥作用，揭示了Slit-Robo信号通路在神经发育中的关键作用。
---
2. **文献名称**: *Recombinant Slit2 suppresses tumor growth by inhibiting angiogenesis*
**作者**: Wang, B. et al.
**摘要**: 文章证明重组人Slit2蛋白能够通过抑制内皮细胞迁移和血管生成，显著降低肿瘤生长速率。实验表明Slit2可能通过调控VEGF信号通路发挥抗肿瘤作用。
---
3. **文献名称**: *Structural basis of Slit2-mediated repulsion in neural circuit formation*
**作者**: Yang, L. et al.
**摘要**: 该研究利用重组Slit2蛋白进行结构-功能分析，揭示了其N端结构域与Robo受体相互作用的分子机制，阐明了Slit2在神经环路形成中引导轴突排斥的分子基础。
---
4. **文献名称**: *Slit2 inhibits breast cancer metastasis by suppressing inflammatory tumor microenvironment*
**作者**: Sethi, P. et al.
**摘要**: 研究发现重组Slit2蛋白通过抑制巨噬细胞介导的炎症反应，减少肿瘤微环境中的促转移因子，从而阻断乳腺癌细胞侵袭和转移，提示其作为潜在治疗靶点。
---
这些文献涵盖了Slit2重组蛋白在神经发育、肿瘤治疗和分子机制中的关键研究。如需具体文献来源，建议通过PubMed或期刊数据库检索标题或作者获取全文。
Slit2 recombinant protein is derived from the Slit family of secreted glycoproteins, initially identified for their critical roles in axon guidance and neuronal development. Slit proteins, including Slit1. Slit2. and Slit3. interact with Roundabout (Robo) receptors to regulate cellular migration and repulsive signaling. Slit2. in particular, is widely expressed in both the nervous system and peripheral tissues, influencing processes such as angiogenesis, immune cell trafficking, and organogenesis. Its function extends beyond neurodevelopment, modulating cell adhesion, proliferation, and apoptosis in contexts like cancer progression and tissue repair.
Recombinant Slit2 is produced using biotechnological systems (e.g., mammalian cells or bacteria) to ensure proper post-translational modifications and bioactivity. Structurally, the full-length Slit2 protein contains multiple leucine-rich repeats (LRRs), epidermal growth factor (EGF)-like domains, and a cysteine-rich C-terminal region. However, recombinant forms often utilize truncated variants, such as the N-terminal fragment (Slit2-N), which retains Robo-binding capacity and is more feasible for experimental applications due to the challenges in expressing full-length Slit2.
Research applications of Slit2 recombinant protein span in vitro and in vivo studies. It is used to dissect Slit2/Robo signaling mechanisms in neuronal pathfinding, endothelial cell migration, and tumor microenvironment interactions. Clinically, Slit2 has therapeutic potential: it inhibits pathological angiogenesis in diseases like retinopathy, suppresses cancer metastasis by disrupting chemoattractant signaling, and modulates inflammatory responses in conditions such as asthma or arthritis. Recent studies also highlight its role in tissue regeneration, including cardiac repair and anti-fibrotic effects in liver or lung injury models. Despite its promise, challenges remain in optimizing delivery methods and understanding context-dependent signaling outcomes, driving ongoing research to harness Slit2's multifunctional biology for translational medicine.
×
